Gogtay, 125 patient aspirin prophylaxis study: 6% higher mortality [p=0.87], 50% lower ventilation [p=0.16], and 49% lower ICU admission [p=0.41] https://c19p.org/gogtay
copied to clipboard
Retrospective analysis of aspirin's role in the severity of COVID-19 pneumonia
et al., World Journal of Critical Care Medicine, doi:10.5492/wjccm.v11.i2.92
Retrospective 125 COVID+ hospitalized patients in the USA, showing no significant differences with aspirin prophylaxis.
|
risk of death, 5.9% higher, RR 1.06, p = 0.87, treatment 12 of 38 (31.6%), control 21 of 87 (24.1%), adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
|
|
risk of mechanical ventilation, 49.8% lower, RR 0.50, p = 0.16, treatment 5 of 38 (13.2%), control 21 of 87 (24.1%), NNT 9.1, adjusted per study, odds ratio converted to relative risk, multivariable.
|
|
risk of ICU admission, 49.2% lower, RR 0.51, p = 0.41, treatment 9 of 38 (23.7%), control 38 of 87 (43.7%), NNT 5.0, adjusted per study, odds ratio converted to relative risk, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Gogtay et al., 9 Mar 2022, retrospective, USA, peer-reviewed, 4 authors, study period March 2020 - April 2020.
Contact:
drgogtay@gmail.com.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.